Hematology Update by LucidQuest Episode 13

🔬🩸 Hematology Updates: CAR-T Approvals, Mutation-Agnostic AML Therapies & Global Trial Milestones

New CAR-T approvals, breakthrough mutation-agnostic AML therapies, and paradigm-shifting clinical trial results are redefining the hematology landscape in 2025.

💡 Key Highlights This Week:

💥 UK approves Autolus’ Aucatzyl CAR-T for r/r ALL with 81% 12-month survival

🧪 Actimab-A shows efficacy across FLT3, TP53, KMT2A, and NPM1 AML mutations

🚀 Ingenium’s Gengleucel NK-cell therapy enters Phase 2 in MRD+ AML

🇪🇺 CHMP backs Calquence + Venetoclax combo for frontline CLL with up to 58% lower progression risk

🧫 Genmab to file sBLA for epcoritamab + R2 combo in relapsed FL

🧠 Genocury’s in vivo CAR-T achieves full remission in DLBCL without lymphodepletion

⚡ BioInvent’s BI-1808 earns FDA Fast Track for mycosis fungoides and Sézary syndrome

✅ EU approves Regeneron’s Lynozyfic for triple-class exposed multiple myeloma with 71% ORR

🎯 Whether you're following CAR-T innovation, targeted radiotherapies, or trial design breakthroughs in blood cancers—this roundup delivers the insights you need to stay informed.

📢 Stay Ahead in Hematology Research!
✅ Like, share, and subscribe for weekly updates on hematologic malignancies, immunotherapies, and global clinical developments
✅ Visit www.lqventures.com for expert healthcare insights and consulting services
✅ Contact LucidQuest at info@lqventures.com for strategic guidance on hematology innovations and clinical research
🔔 Turn on notifications so you never miss an update!

#Hematology #CAR_T #ALL #AML #CLL #DLBCL #FL #MultipleMyeloma #CD19 #BCMA #TNFR2 #ClinicalTrials #BiotechNews #LucidQuest #PharmaInnovation #BloodCancer

Видео Hematology Update by LucidQuest Episode 13 канала LucidQuest